Overview

Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
The primary object of this study is to confirm the superiority of tianeptine compared to escitalopram on effects that improves subjective and objective cognitive impairments in patients suffering from major depressive disorder.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Citalopram
Dexetimide
Tianeptine
Criteria
Inclusion Criteria:

1. Patients fulfilling DSM-IV-TR(American Psychiatric Association, 4thedition, 2000)
criteria for Major Depressive Disorder diagnosis

2. The male or female patients aged more than 40 years

3. Patients able to hand in written informed consent before his/her participation in this
clinical study

4. Women of childbearing potential with negative pregnancy test during screening phase
and entire study period (during entire study period, able to clearly agree with
effective contraception such as contraceptive pill, progesterone injection,
levonorgestrel implant, estrogen ring, transdermal contraceptive agent, intra-uterine
contraceptive device, sterilization operation of husband, and double contraceptive
method (e.g. combination of condom, pessary, spermicide, etc. ))

5. Patients who have subjective cognitive impairment, or who have objective cognitive
impairment (MMSE ≤26) without subjective cognitive impairment

6. HAM-D(17-items) total score ≥ 16

Exclusion Criteria:

1. Patients meeting more than one following patient characteristics

1. Patients fulfilling DSM-IV-TR current or past diagnosis of any psychiatric
disorders other than major depressive disorder (i.e. manic or hypomanic episode,
schizophrenia, delirium, dementia, eating disorder, obsessive-compulsive
disorder, panic disorder, post-traumatic stress disorder, major depressive
disorder with psychotic features, mental retardation, organic brain disorder, or
psychiatric disorders due to general medical condition, according to DSM-IV-TR)

2. Patients with any substance-related disorder (excluding nicotine) within the past
12 months, as defined in DSM-IV-TR

3. Patients with a history or presence of any neurological disorders (e.g. multiple
sclerosis, seizure, etc.)

4. Patients with any axis II disorder that prone to interfere with the evaluation of
the study

2. Patients with a history or presence of any hypersensitivity to tianeptine,
escitalopram or other drugs

3. Patients who receive formal psychotherapy (e.g. cognitive behavioral therapy,
insight-oriented psychoanalysis, interpersonal therapy, etc.) and who have a plan for
getting psychotherapy

4. Patients with any clinically significant abnormality (e.g. hepatic failure, renal
failure, cardiovascular disorder, respiratory disorder, gastrointestinal disorder,
endocrine disorder, neurological disorder, inflammatory disorder, neoplasm, metabolic
disorder, etc.)

5. Patients who have abnormal ECG and a significant disease according to the
investigator's judgment

6. Patients with any chronic liver or kidney disease

7. Patients with a family history of long QT syndrome

8. Patients previously not responders to tianeptine or escitalopram in the treatment of
major depressive disorder

9. Patients who have a suicide risk according to the investigator's judgment